Employees: 1,738
Size Hainan Haiyao (000566.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $642M, the 3088th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.75 on 18 Nov 2026.
Performance Over six months the shares fell 18.1%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue fell 18.0% over the last twelve months (peer median +12.2%); the operating margin is -50.0% (peer median 10.0%).
Valuation It trades at 10.6× enterprise value to sales against a peer median of 3.2× (4th most expensive of 17).
Capital Return on invested capital runs 10.4 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥673M | CN¥825M | CN¥971M | CN¥1.46B | CN¥1.76B |
| Revenue growth | — | -15% | -33% | -17% | — |
| Gross profit | CN¥239M | CN¥129M | CN¥265M | CN¥519M | CN¥706M |
| EBITDA | n/a | -CN¥47.2M | -CN¥460M | CN¥163M | CN¥29.2M |
| Net income | -CN¥533M | -CN¥430M | -CN¥1.53B | -CN¥106M | CN¥10.5M |
| Free cash flow | -CN¥115M | -CN¥50.9M | -CN¥184M | -CN¥73.5M | -CN¥113M |
| Capital expenditure | CN¥154M | CN¥143M | CN¥176M | CN¥211M | CN¥264M |
| Total debt | CN¥3.21B | CN¥4.82B | CN¥4.56B | CN¥4.24B | CN¥4.04B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000566.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.1% | -8.1% | 8th lowest of 20 |
| 6-month return | -18.1% | -17.5% | 10th lowest of 20 |
| Distance from 52-week high | -59.4% | -36.4% | 5th lowest of 20 |
| Revenue growth (TTM) | -18.0% | +12.2% | 2nd lowest of 17 |
| Operating margin | -50.0% | 10.0% | lowest of 16 |
| EV / Sales | 10.6× | 3.2× | 4th most expensive of 17 |
| ROIC minus cost of capital | -10.4 pp | -3.7 pp | 4th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |